ARTICLE | Company News

Shire licenses recombinant immunoglobulin from AB Biosciences

February 2, 2018 8:21 PM UTC

AB Biosciences Inc. (Allston, Mass.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to develop and commercialize its pan receptor interacting molecule (PRIM) program. PRIM is a recombinant immunoglobulin that AB Biosciences said has shown "enhanced biological activity" in preclinical models of autoimmune and inflammatory diseases compared with approved IV immunoglobulin (IVIG) therapies.

AB Biosciences said PRIM uses its oligomeric Fc technology platform and contains three immunoglobulin constant regions that can bind to Fc receptors similarly to that of immune complexes...

BCIQ Company Profiles

AB Biosciences Inc.

Shire plc